Pregnancy and infant outcomes among HIV-infected women taking long-term art with and without tenofovir in the DART trial

PLoS Medicine

Volumn 9, Issue 5, 2012, Pages

  Gibb, Diana M ^a   Kizito, Hilda ^b   Russell, Elizabeth C ^a   Chidziva, Ennie ^c   Zalwango, Eva ^d   Nalumenya, Ruth ^e   Spyer, Moira ^a   Tumukunde, Dinah ^b   Nathoo, Kusum ^f   Munderi, Paula ^d   Kyomugisha, Hope ^b   Hakim, James ^c   Grosskurth, Heiner ^d   Gilks, Charles F ^g   Walker, A Sarah ^a   Musoke, Phillipa ^e  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e MAKERERE UNIVERSITY   (Uganda)

^f UNIV OF ZIMBABWE MEDICAL SCHOOL   (Zimbabwe)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CREATININE; HEMOGLOBIN; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PHOSPHATE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; LAMIVUDINE PLUS ZIDOVUDINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BURN; CHILD; CHILD GROWTH; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HEALTH STATUS; HIV TEST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFANT FEEDING; INFANT MORTALITY; LIVE BIRTH; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEASLES; MORTALITY; OBSERVATIONAL STUDY; PATIENT MONITORING; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SEPSIS; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; STILLBIRTH; VIRUS TRANSMISSION; BREAST FEEDING; CAUSE OF DEATH; CLINICAL TRIAL; CONGENITAL DISORDER; CONTROLLED CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG COMBINATION; DRUG EFFECT; FRACTURE; GROWTH; MALE; NEWBORN; PREGNANCY; PREVALENCE; STATISTICS; UGANDA; VERTICAL TRANSMISSION; ZIMBABWE;

ABORTION, SPONTANEOUS; ADENINE; ADULT; ANTI-HIV AGENTS; BODY HEIGHT; BODY WEIGHT; BREAST FEEDING; BURNS; CAUSE OF DEATH; CHILD, PRESCHOOL; CONGENITAL ABNORMALITIES; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; GROWTH; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MALE; MEASLES; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PREVALENCE; RESPIRATORY TRACT INFECTIONS; UGANDA; ZIDOVUDINE; ZIMBABWE;

EID: 84861553641     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001217     Document Type: Article

References (60)

1. Kesho Bora Study Group (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 11: 171-180.
2. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, et al. (2010) Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 362: 2282-2294.
3. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 revision Geneva WHO.
4. World Health Organization (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Available: http://www.who.int/hiv/pub/2010progressreport/report/en/index.html. Accessed 18 April 2010.
5. World Health Organization (2011) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2011. Available: http://www.who.int/hiv/pub/progress_report2011/en/index.html. Accessed 10 December 2011.
6. PARTNERS PrEP study (2011) Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa Seattle (Washington) International Clinical Research Center (ICRC).
7. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
8. Antiretroviral Pregnancy Register (2011) Interim Report 1 January 1989 through 31 January 2011. Available: http://www.apregistry.com/forms/interim_report.pdf. Accessed 24 August 2011.
9. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, et al. (2009) Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med 10: 397-406.
10. McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, et al. (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376: 1329-1337.
11. Munderi P, Wilkes H, Tumukunde D, Chidziva E, Nalumenya R, et al. (2009) Pregnancy rates & outcomes among women on triple-drug antiretroviral therapy in the DART trial [Abstract WEPEB261]. In: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 19-22 July 2009; Capetown, South Africa.
12. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, et al. (2010) Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med 7: e1000229 doi:10.1371/journal.pmed.1000229.
13. UNAIDS (2008) Total fertility rate. Available: http://data.un.org/Data.aspx?d=SOWC&f=inID%3A127. Accessed 18 January 2011.
14. DART Trial Team (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375: 123-131.
15. World Health Organization (2006) Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach Geneva WHO.
16. DART Trial Team (2008) Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 13: 6-16.
17. Bayley N, (1993) Bayley scales of infant development. 2nd edition San Antonio (Texas, US) The Psychological Corporation.
18. Division of AIDS (DAIDS) (2004) Table for the grading of the severity of adult and pediatric adverse events (December 2004). Available: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.doc. Accessed 16 April 2012.
19. NIH Division and Infectious Diseases (DMID) (2007) Pediatric toxicity tables (November 2007). Available: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidpedtox.pdf. Accessed 16 April 2012.
20. WHO Child Growth Standards Group (2009) Growth velocity based on weight, length, and head circumference: methods and development Geneva WHO.
21. Cortinovis I, Vella V, Ndiku N, Milani S, (1997) Weight, height and arm circumference of children under 5 in the district of Mbarara, south-west Uganda. Ann Hum Biol 24: 557-568.
22. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, et al. (2010) Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr 54: 63-70.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents (2011) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 20 January 2011.
24. European AIDS Clinical Society (2011) Guidelines for clinical management and treatment of HIV-infected adults in Europe. Version 6. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6_english.pdf. Accessed 16 April 2012.
25. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour M, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Eng J Med 365: 493-505.
26. Centers for Disease Control and Prevention (2011) Results of FEM-PrEP clinical trial examining pre-exposure prophylaxis (PrEP) for HIV prevention among heterosexual women Atlanta (Georgia) CDC.
27. Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, et al. (2007) Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr 45: 269-273.
28. Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, et al. (2008) The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr 47: 93-100.
29. Benaboud S, Pruvost A, Coffie PA, Ekouevi DK, Urien S, et al. (2011) Breast milk concentrations of tenofovir and emtricitabine in HIV-1 infected women in Abidjan TEmAA Step 2 (ANRS 12109). Antimicrob Agents Chemother 55: 1315-1317.
30. Hirt D, Urien S, Ekouevi DK, Rey E, Arrive E, et al. (2009) Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 85: 182-189.
31. Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, et al. (2004) Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 48: 1469-1487.
32. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, et al. (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52: 3144-3160.
33. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB, (2002) Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 29: 207-220.
34. Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, et al. (2007) Metropolitan Atlanta Congenital Defects Program 40th Anniversary Edition Surveillance Report: Reporting birth defects surveillance data 1968-2003. Birth Defects Res A Clin Mol Teratol 79: 65-93. Erratum: 2008;82:41-62.
35. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA, (2007) Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 21: 1019-1026.
36. Kourtis AP, Schmid CH, Jamieson DJ, Lau J, (2007) Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 21: 607-615.
37. Townsend C, Schulte J, Thorne C, Dominguez KI, Tookey PA, et al. (2010) Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG 117: 1399-1410.
38. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R, (2008) Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 152: 582-584.
39. Soler-Palacin P, Melendo S, Noguera-Julian A, Fortuny C, Navarro ML, et al. (2011) Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 25: 171-176.
40. Judd A, Boyd KL, Stohr W, Dunn D, Butler K, et al. (2010) Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 24: 525-534.
41. Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, et al. (2009) Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J 28: 204-209.
42. Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, et al. (2008) Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 19: 913-918.
43. Peters B, Isohanni H, Tillet S, al et, (2010) Fracture risk in HIV and the need for guidelines: the Probono-1 trial [Abstract P099]. In: Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK; 7-11 November 2010.
44. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, et al. (2009) Continuous antiretroviral therapy decreases bone mineral density. AIDS 23: 1519-1529.
45. Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, et al. (2010) High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24: 2827-2833.
46. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, et al. (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51: 963-972.
47. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, et al. (2006) Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118: e711-e718.
48. Vigano A, Zuccotti GV, Puzzovio M, Pivetti V, Zamproni I, et al. (2010) Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. Antivir Ther 15: 1053-1058.
49. Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET, (2008) Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 42: 1581-1585.
50. Siberry GK, Williams PL, Mendez H, Seage GR 3rd, Jacobson DL, et al. (2012) Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS In press.
51. Perinatal HIV Guidelines Working Group (2010) Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed 20 January 2011.
52. Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, et al. (2011) Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr 56: 131-138.
53. World Health Organization (2006) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach (2006 version) Geneva WHO.
54. Kagaayi J, Gray RH, Brahmbhatt H, Kigozi G, Nalugoda F, et al. (2008) Survival of infants born to HIV-positive mothers, by feeding modality, in Rakai, Uganda. PLoS One 3: e3877 doi:10.1371/journal.pone.0003877.
55. Kuhn L, Sinkala M, Semrau K, Kankasa C, Kasonde P, et al. (2010) Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers. Clin Infect Dis 50: 437-444.
56. Creek TL, Kim A, Lu L, Bowen A, Masunge J, et al. (2006) Hospitalization and mortality among primarily nonbreastfed children during a large outbreak of diarrhea and malnutrition in Botswana, 2006. J Acquir Immune Defic Syndr 53: 14-19.
57. World Health Organization (2010) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach (2010 version) Geneva WHO.
58. Rajaratnam JK, Marcus JR, Flaxman AD, Wang H, Levin-Rector A, et al. (2010) Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet 375: 1988-2008.
59. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, et al. (2005) Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 366: 1182-1188.
60. Moodley D, Esterhuizen TM, Pather T, Chetty V, Ngaleka L, (2009) High HIV incidence during pregnancy: compelling reason for repeat HIV testing. AIDS 23: 1255-1259.